Drug-Eluting Balloons

This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.

News | Drug-Eluting Balloons

November 10, 2021 — Biosensors International Group Ltd., a developer and manufacturer of innovative medical devices ...

Home November 10, 2021
Home
News | Drug-Eluting Balloons

October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-breaking ...

Home October 20, 2021
Home
News | Peripheral Artery Disease (PAD)

June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...

Home June 07, 2021
Home
News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Example of an angioplasty balloon catheter being expanded inside an artery to push atherosclerotic plaque and thrombus out of the way to reopen the vessel lumen to increase or reopen bloodflow. Balloon catheters are used to revascularize patients with heart attacks and to deploy stents to prop open the expended vessel.
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
News | Drug-Eluting Balloons

March 12, 2021 — Philips Healthcare announced the final, five-year results of two major randomized controlled trials ...

Home March 12, 2021
Home
News | Drug-Eluting Balloons

November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated ...

Home November 03, 2020
Home
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab

October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit ...

Home October 18, 2020
Home
News | Drug-Eluting Balloons

October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the ...

Home October 18, 2020
Home
Videos | Drug-Eluting Balloons

Juan F. Granada, M.D., CEO of the Cardiovascular Research Foundation (CRF) worked on preclinical development work for a ...

Home September 09, 2020
Home
The Philips Healthcare Stellarex drug-coated balloon (DCB). It is cleared for use in peripheral vessels and treatment of failing AV access.
Feature | Drug-Eluting Balloons | Dave Fornell, Editor

Drug-coated balloons (DCB), also referred to as drug-eluting balloons (DEB), were created as a way to reduce very high ...

Home August 06, 2020
Home
News | Drug-Eluting Balloons

July 7, 2020 – MedAlliance announced enrollment of the first patient in its study of Selution SLR 0.014 drug-eluting ...

Home July 07, 2020
Home
Comparison Charts

Drug-coated balloons (DCB), also referred to as drug-eluting balloons, are used to treat peripheral and coronary artery ...

Home
Home
News | Drug-Eluting Balloons

June 19, 2020 — iVascular SLU announced the global launch of Essential Pro, a novel coronary artery drug-coated balloon ...

Home June 19, 2020
Home
News | Drug-Eluting Balloons

June 17, 2020 — MedAlliance announced its second CE mark approval for its Selution SLR 0.014 percutaneous transluminal ...

Home June 18, 2020
Home
Subscribe Now